Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Relatlimab FDC in Unresectable or Metastatic Melanoma in India
NCT07459543Phase 4Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2026
- Primary completion
- May 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in melanoma, sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events at 30 weeks, Incidence of drug-related adverse events at 30 weeks and 6 more. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT07459543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459543.